Orexigen Therapeutics — Investor Presentation (December 2010)
25 slides from Orexigen Therapeutics's investor presentation, Dec 17, 2010
Slide 1: Investor Presentation, December 2010
Investor Presentation Investor Presentation December 2010 December 2010 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “assuming” and similar expressions are intended to identify forwa
Slide 3: Realizing the Vision: Industry Leader in Obesity Therapeutics
Realizing the Vision Industry Leader in Obesity Therapeutics PRODUCTS Contrave ® – NDA under review by FDA Empatic™ – Preparing for Phase III STRATEGY/EXECUTION Successful Execution on All Major Milestones to Date Gain High Quality Partners for Global Commercialization RESOURCES Powerful Partner for
Slide 4: 2010 – A Year of Strong Execution
2010 – A Year of Strong Execution 2010 – A Year of Strong Execution Q1 Q2 Q3 Q4 Filed NDA NDA Accepted by FDA Clinical Results Published in The Lancet and Obesity Signed Takeda Partnership Positive Advisory Committee Meeting
Slide 5: Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm
Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm Increase in Obesity 16% 34% 43% Serious Disease Attributable to Obesity Treatment Options Needed Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm Source: http://www.cdc.gov; http://www.fightchronicdisease.org; F
Slide 6: Slide 6
Slide 7: Key Results from Advisory Committee
Key Results from Advisory Committee 13:7 on Approvability 11:8 – Outcomes Trial should be Run Post-Approval (Not Pre-approval) Major Takeaways Key Results from Advisory Committee Efficacy Met FDA Guidance Strong Support for Comprehensive Risk Mitigation Strategy Desire for a Post-Approval Outcomes S
Slide 8: Typical Response to Weight Loss Therapy is not Uniform
Typical Response to Weight Loss Therapy is not Uniform COR-I Weight Loss Distribution (Contrave32) -40 -30 -20 -10 Typical Response to Weight Loss Therapy is not Uniform
Slide 9: Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response
Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response COR-I Weight Loss Distribution (Contrave32) -40 -30 -20 -10 Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response Our Focus: Patients Who Lose 5% <5% weight loss
Slide 10: Slide 10
Slide 11: Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss
Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss Weight Loss Distribution 0% - 5% Weight loss 10% - 15% Weight Loss Avg Wt Loss = 26.7 lbs >15% Wt Loss Avg Wt Loss = 43.9 lbs Weight Gain 5% - 10% Weight Loss Avg Wt Loss = 17.0 lbs Contrave Early Responders Go on to Achiev
Slide 12: Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters
Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Contrave32 N=1038 Proportion w/ 5% Wt Loss Wk 16 Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Improvement (Standardized Mean Change from Baseline) Contrave32 N=1038 Placebo N=254
Slide 13: Contrave: Well Characterized Safety Profile
Contrave: Well Characterized Safety Profile Delivers Safety Experience Consistent with 20+ Year History of Underlying Agents Known Areas of Focus – CV Effects, Seizure, Psychiatric Effects, Creatinine Meets FDA Guidance for Patient Exposure for Evaluation of Safety and Tolerability with >4,500 Patie
Slide 14: Slide 14
Slide 15: Post-approval Outcomes Trial Represents Significant Opportunity for Orexigen
Post-approval Outcomes Trial Represents Significant Opportunity for Orexigen Beneficial outcomes predicted based on cardiometabolic improvements -- Demonstrating outcomes benefit could be transformational for Contrave and the obesity field Proposing large simple trial (LST) -- Streamlined, practical
Slide 16: Takeda Is the Ideal Partner for Contrave
Takeda Is the Ideal Partner for Contrave SCALE Top 15 Pharma Significant U.S. Presence Primary Care Focus COMMITMENT TO OBESITY Partnership with Amylin Stated Strategy DOMAIN EXPERTISE Leader in Cardiometabolic Care Excellence in Life Cycle Management POWERFUL BRAND BUILDER Actos ~$3B in U.S. Sales
Slide 17: Competitive Product Profile Attractive to Patients
Competitive Product Profile Attractive to Patients Women Dominate the Market 1/3 to 1/2 Experienced Market-Meaningful Weight Loss No Addictive Concerns 73% Competitive Product Profile Attractive to Patients % of Patients Losing 10% of Body Weight after Completing 1 year of Treatment Avg Loss 34 lbs
Slide 18: Contrave: Keys to Commercial Success
Contrave: Keys to Commercial Success Blockbuster Market Size Market Growth Significant Unmet Need – Limited Competition Diet & Lifestyle Modifications Contrave: Differentiated Profile Takeda: Heavily Resourced Contrave: Keys to Commercial Success Source: CDC (2009) 103M US Obesity Rate Growth Obesit
Slide 19: We Partnered Early for the Significant Activities Required for a Quality Launch
We Partnered Early for the Significant Activities Required for a Quality Launch Sales Force Professional Patient Brand Development Market Development Managed Markets; Government Affairs We Partnered Early for the Significant Activities Required for a Quality Launch Sales Aids Direct Mail Physician E
Slide 20: PHI
PHI
Slide 21: Empatic: Second Late Stage Obesity Program with Complementary Profile
Empatic: Second Late Stage Obesity Program with Complementary Profile Empatic: Second Late Stage Obesity Program with Complementary Profile Observed Case Analysis Key to Multi-Solution Approach - High Efficacy - Different MOA than Contrave - Helps Orexigen Meet Differing Patients Needs Safety Profil
Slide 22: —_>—sFZ/
—_>—sFZ/
Slide 23: No Foreseeable Need to Finance
No Foreseeable Need to Finance Strong Balance Sheet Near-Term Milestones Low Burn Rate No Foreseeable Need to Finance $50M Payment from Takeda in Q3 $100M of Cash and Investments as of 9/30/10 $100M in Milestones Achievable Between Now and Product Launch Additional Milestones for New Potential Colla
Slide 24: Realizing the Vision: Industry Leader in Obesity Therapeutics
Realizing the Vision Industry Leader in Obesity Therapeutics PRODUCTS Contrave ® - NDA under review by FDA Empatic™ – Preparing for Phase III STRATEGY/EXECUTION Successful Execution on All Major Milestones to Date Gain High Quality Partners for Global Commercialization RESOURCES Powerful Partner for
Slide 25: Slide 25
Orexigen Therapeutics — Investor Presentation (December 2010) on 6ix